Related Experiment Video
Updated: Jul 15, 2026

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
Published on: June 7, 2016
Endothelin-1 accentuates the proatherosclerotic effects associated with C-reactive protein
Danny Ramzy1, Vivek Rao, Laura C Tumiati
1Division of Cardiac Surgery, University of Toronto, Toronto, Ontario, Canada.
Insights
Endothelin-1 accentuates C-reactive protein's negative impact on nitric oxide production by inhibiting protein kinase C. This suggests targeting endothelin-1 and protein kinase C could improve vascular health and reduce atherosclerosis.
Area of Science:
- Cardiovascular Biology
- Inflammation Research
- Endothelial Function
Background:
- C-reactive protein (CRP) is a proinflammatory marker implicated in atherosclerosis development.
- Endothelin-1 (ET-1) and nitric oxide (NO) homeostasis are vital for vascular health, regulating vasomotor function and endothelial surface properties.
- CRP impairs endothelial NO production, a process potentially modulated by protein kinase C (PKC).
Purpose of the Study:
- To investigate whether ET-1 exposure modifies CRP's effects on endothelial NO production.
- To determine the role of PKC in the interaction between CRP and ET-1 on NO homeostasis.
- To explore potential therapeutic targets for mitigating CRP-induced proatherosclerotic effects.
Main Methods:
- Human endothelial cells were exposed to CRP, ET-1, or both, alongside a control.
- Measurements included endothelial NO synthase (eNOS) expression, total NO production, and PKC translocation and activity.
- Specific PKC isoforms, such as PKC lambda, were assessed.
Main Results:
- Both CRP and ET-1 individually reduced eNOS expression and NO production.
- Coincubation synergistically reduced NO production by 70% compared to control.
- CRP and ET-1 synergistically inhibited PKC lambda translocation and activity, with CRP alone also reducing PKC activity.
Conclusions:
- ET-1 exacerbates CRP-induced impairment of endothelial NO production through synergistic inhibition of PKC lambda.
- Targeting ET-1 and stimulating PKC may offer a novel therapeutic approach to restore vascular NO homeostasis.
- These findings highlight a potential strategy to counteract the proatherosclerotic actions of CRP.
Objectives:
The proinflammatory marker C-reactive protein has been demonstrated to play a role in the development of atherosclerosis. Endothelin-1 and nitric oxide homeostasis is crucial for normal vasomotor function, limiting inflammatory activation and maintaining a nonthrombogenic endothelial surface. In addition to its vasoactive properties, endothelin-1 is also an inflammatory cytokine. We have previously demonstrated that C-reactive protein impairs endothelial cell nitric oxide production. Protein kinase C, an important signal transducer within the cell, is involved in several cellular responses to external stimuli. We therefore sought to determine whether endothelin-1 exposure modulates C-reactive protein's effects on nitric oxide production via protein kinase C.
Methods:
Endothelial cells were incubated with C-reactive protein (200 microg), endothelin-1 (100 nM), C-reactive protein + endothelin-1, or phosphate-buffered saline solution (control) for 24 hours. After exposure, endothelial nitric oxide synthase expression was determined in addition to total nitric oxide production and protein kinase C translocation and activity.
Results:
Endothelial nitric oxide synthase protein expression was reduced following incubation with C-reactive protein and endothelin-1 treatment compared with baseline by 40% and 45%, respectively (P = .04); however, no additive effects were seen with coincubation. C-reactive protein produced a 47% decrease in nitric oxide production compared with control. Coincubation with endothelin-1 resulted in a synergistic 70% reduction in nitric oxide production (P = .001). C-reactive protein exposure inhibited translocation of protein kinase C lambda compared with control (P = .01). Furthermore, coincubation of C-reactive protein with endothelin-1 led to a synergistic inhibition of protein kinase C lambda translocation (P = .01). C-reactive protein exposure reduced protein kinase C activity by 40% compared with control (P = .02), although coincubation with endothelin-1 had a synergistic reduction in activity (P = .02).
Conclusions:
Our results indicate that endothelin-1 exposure accentuated C-reactive protein's impairment of endothelial nitric oxide production via synergistic inhibition of protein kinase C lambda translocation and activity. Our investigations suggest that endothelin-1 inhibition and protein kinase C stimulation may provide a novel therapeutic strategy to improve vascular nitric oxide homeostasis and mitigate the proatherosclerotic effects of C-reactive protein.
Related Concept Videos
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Action of β1 Blockers
Antihypertensive Drugs: Direct Renin Inhibitors